home / stock / lctx / lctx quote
Last: | $0.893 |
---|---|
Change Percent: | 0.2% |
Open: | $0.9167 |
Close: | $0.893 |
High: | $0.9303 |
Low: | $0.8372 |
Volume: | 959,782 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.893 | $0.9167 | $0.893 | $0.9303 | $0.8372 | 959,782 | 07-05-2024 |
$0.9185 | $0.94 | $0.9185 | $0.9433 | $0.9103 | 769,663 | 07-04-2024 |
$0.9185 | $0.94 | $0.9185 | $0.9433 | $0.9103 | 769,663 | 07-03-2024 |
$0.9321 | $0.95 | $0.9321 | $0.9599 | $0.9235 | 527,336 | 07-02-2024 |
$0.9541 | $0.98 | $0.9541 | $0.9801 | $0.95 | 1,027,541 | 07-01-2024 |
$0.9973 | $1.02 | $0.9973 | $1.02 | $0.94 | 3,302,992 | 06-28-2024 |
$1.03 | $0.9 | $1.03 | $1.03 | $0.9 | 1,078,967 | 06-27-2024 |
$0.9 | $0.9135 | $0.9 | $0.9212 | $0.9 | 593,252 | 06-26-2024 |
$0.9141 | $0.9341 | $0.9141 | $0.9499 | $0.91 | 464,201 | 06-25-2024 |
$0.9224 | $0.9022 | $0.9224 | $0.9655 | $0.9022 | 954,692 | 06-24-2024 |
$0.9031 | $0.8926 | $0.9031 | $0.92 | $0.89 | 608,195 | 06-21-2024 |
$0.8942 | $0.88 | $0.8942 | $0.9266 | $0.84 | 848,429 | 06-20-2024 |
$0.89 | $0.9038 | $0.89 | $0.9313 | $0.88 | 1,292,195 | 06-19-2024 |
$0.89 | $0.9038 | $0.89 | $0.9313 | $0.88 | 1,292,195 | 06-18-2024 |
$0.9051 | $0.9103 | $0.9051 | $0.91945 | $0.895 | 1,025,862 | 06-17-2024 |
$0.9194 | $0.93 | $0.9194 | $0.94 | $0.91 | 544,801 | 06-14-2024 |
$0.9291 | $0.96 | $0.9291 | $0.9606 | $0.9001 | 539,804 | 06-13-2024 |
$0.9467 | $0.9786 | $0.9467 | $0.985 | $0.9363 | 425,229 | 06-12-2024 |
$0.9681 | $0.93 | $0.9681 | $0.9687 | $0.9151 | 651,781 | 06-11-2024 |
$0.925 | $0.95 | $0.925 | $0.98 | $0.91 | 1,382,135 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...